Hidden heart risks in kids with lupus: a new study aims to find them early
NCT ID NCT07545408
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 70 children and teens with juvenile lupus to check for early signs of heart disease using an ultrasound of the neck artery. Researchers will see if things like cholesterol, blood pressure, and lupus activity are linked to artery thickness. No treatment is given—only measurements and comparisons to healthy children.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 70 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Aug 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Childrens diagnosed with systemic lupus erythematosus
- Ages
-
0 to 18 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: \- Children and adolescents aged under 18 years diagnosed with JSLE according to the Systemic Lupus International Collaborating Clinics ( SLICC 2012 Criteria ). Disease duration of at least 6 months. Under regular follow-up at the study institution. Exclusion Criteria: * Patients with other autoimmune or connective tissue overlap diseases (e.g., mixed connective tissue disease, juvenile dermatomyositis). Patients with congenital heart disease or known structural cardiovascular abnormalities. Patients with chronic kidney disease stage 4 or 5. Patients currently receiving lipid-lowering therapy prior to enrolment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atherosclerosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hunting the hidden warning signs of heart attacks and strokes
- Heart risk in rheumatoid arthritis: could a blood vessel drug help?
- Can calming inflammation shield the heart?
- Could an old malaria drug shield hearts in kidney disease?
- A new multi-test approach may spot hidden blood vessel damage before symptoms appear
- Can a blood vessel drug beat aspirin at preventing heart attacks in diabetes?